Diversity, equity and inclusion (DE&I) continues to be a challenge for drug and medical device developers. While there has been some improvement in clinical trials, Ali Pashazadeh, Treehill Partners CEO, and other guests at Biospace roundtable discussion hosted by Lori Ellis, note that unless there is a commercial or regulatory need, DE&I is still an afterthought for many developers when designing clinical trials.
Listen to the podcast on Biospace:
https://www.biospace.com/challenging-research-models-to-improve-health-equity